Meditech Formula 2 Injection Recalled for Superpotent Drug Ingredient
Meditech Laboratories is recalling Formula 2 Injection vials because one ingredient exceeded assay specifications, making the drug superpotent.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classified this as an FDA Class II recall. Per the rubric, FDA Class II recalls involving significant injury or property damage reports, or structural defects, are rated Severe. While no specific injuries are reported in the text, the 'superpotent' nature of the drug and the agency's Class II classification align with the Severe criteria for significant risk.
Plain-English summary
Meditech Laboratories, Inc. is recalling 1,320 vials of Formula 2 (Papaverine 9 mg, Phentolamine 1 mg, Atropine 0.1 mg, PGE 10 mcg/mL) Injection. The recall affects 5 mL vials, prescription only, with Lot # 110115-2 and an expiration date of 01/01/16. The product was distributed nationwide.
The recall was initiated because the product is classified as a superpotent drug, with one ingredient found to be above assay specification. This deviation from the specified potency levels poses a risk to patients using the medication.
Patients and healthcare providers should stop using the affected vials and contact their healthcare provider or pharmacist for guidance. The recalling firm is Meditech Laboratories, Inc., located in Las Vegas, Nevada.
The recalled product
- Product
- Formula 2 (Papaverine 9 mg, Phentolamine 1 mg, Atropine 0.1 mg, PGE 10 mcg/mL) Injection, 5 mL vials, Rx only, Meditech Laboratories, Inc., 3200 Polaris Ave., Suite 27, Las Vegas, NV 89102.
- Manufacturer
- Meditech Laboratories, Inc
- Category
- Drug — Injection
- Affected units
- 1,320
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 110115-2
- Exp 01/01/16
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 7 recalled by Meditech Laboratories, Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 7 products in this recall →Related recalls
Same manufacturer · Meditech Laboratories, Inc
See all →- SevereMeditech Formula 9 Injection Recalled for Sterility Assurance Issues
FDA (Drugs) · 2016-04-13
- ModerateMeditech Formula 1 Injection Recalled Due to Expired Active Ingredient
FDA (Drugs) · 2016-04-13
- SevereMeditech Formula 0 Injection Recalled for Sterility Assurance Issues
FDA (Drugs) · 2016-04-13
- SevereMeditech Formula 4 Injection Recalled for Sterility Assurance Issues
FDA (Drugs) · 2016-04-13
- ModerateMeditech Formula 3 Injection Recalled Due to Expired Active Ingredient
FDA (Drugs) · 2016-04-13
Same hazard · superpotent drug
See all →- HighLevothyroxine Sodium Tablets Recalled Due to Potency Failures
FDA (Drugs) · 2024-12-18
- SevereLupin Recalls Cefprozil Oral Suspension Due to Superpotent Drug Concerns
FDA (Drugs) · 2021-04-21
- ModerateRocky Mountain Sunscreen Lip Balm Recalled for Excess Octisalate
FDA (Drugs) · 2020-09-02
- CriticalFerring Recalls STIMATE Nasal Spray Due to Superpotent Drug Risk
FDA (Drugs) · 2020-08-26
- CriticalFerring Recalls DDAVP Nasal Spray Due to Superpotent Drug Risk
FDA (Drugs) · 2020-08-26